Phase 3 Kidney Cancer Trial, Recruiting NCT07092566 Sponsor: Wake Forest University Health Sciences Condition: Kidney Cancer
Back to Kidney Cancer

Phase 3 Kidney Cancer Trial, Recruiting

NCT07092566
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be able to understand and be willing to sign a consent form approved by an ethics review board
  • You must be 18 years old or older at the time you sign the consent form
  • You must be scheduled to have a robotic surgery to remove all or part of a kidney

Who may not be able to join:

  • You may not be eligible if the trial doctor decides you are not a suitable candidate to receive the specific nerve block or pain medication used in this study (confirm with trial site)
  • You may not be eligible if you are currently pregnant
  • You may not be eligible if you have been regularly using opioid pain medications (such as morphine or similar drugs) at a significant daily dose in the 30 days before joining the trial
  • You may not be eligible if you have a serious uncontrolled health condition, such as an active infection, heart failure, unstable chest pain, an irregular heartbeat, or a mental health or personal situation that might make it difficult to follow the study requirements
  • You may not be eligible if you have a known allergy to either of the specific medications used in this study (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
14 November 2025
Est. completion
1 October 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) pain intensity scores through 7 days (168 hours) for participants receiving Exparel vs. R.E.C.K.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov